MedTrace Logo

Monotherapy With Letrozole in Tubal Pregnancy

NCT05839561 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-11-18

No results posted yet for this study

Summary

It is hypothesized that the inhibition of estradiol production by letrozole may interfere with physiological effects of progesterone necessary to maintain the pregnancy. Treatment of tubal pregnancy with letrozole would allow to avoid the adverse effects of methotrexate (MTX) in women refusing surgery. The aim was to compare the effectiveness of letrozole with MTX in the management of tubal pregnancy.

Conditions

  • Tubal Pregnancy Unruptured

Interventions

DRUG

Letrozole as monotherapy

Letrozole 5 mg daily orally for 10 days from day 0

DRUG

MTX as monotherapy

MTX in a single dose of 100 mg intravenously on day 0

Sponsors & Collaborators

  • Jagiellonian University

    lead OTHER

Principal Investigators

  • Robert Jach, Prof., Ph.D. · Jagiellonian University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-01
Primary Completion
2022-12-30
Completion
2023-06-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05839561 on ClinicalTrials.gov